SNDX
NASDAQSyndax Pharmaceuticals Inc.
Price$21.04-1.20 (-5.40%)
01:30 PM07:45 PM
News · 26 weeks42-50%
2025-10-262026-04-19
Mix2490d
- Insider11(46%)
- Other8(33%)
- SEC Filings3(13%)
- Earnings2(8%)
Latest news
25 items- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- SECSEC Form S-8 filed by Syndax Pharmaceuticals Inc.S-8 - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSEC Form 10-K filed by Syndax Pharmaceuticals Inc.10-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer ther
- PRSyndax Announces Participation in March Investor ConferencesNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.Leerink Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday,
- PRSyndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the
- INSIDERChief Executive Officer Metzger Michael A sold $360,819 worth of shares (17,159 units at $21.03), decreasing direct ownership by 3% to 491,690 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERChief Financial Officer Goldan Keith A. sold $71,705 worth of shares (3,410 units at $21.03), decreasing direct ownership by 2% to 140,429 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Syndax Pharmaceuticals Inc.SCHEDULE 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- INSIDERChief Executive Officer Metzger Michael A was granted 217,600 shares and sold $152,835 worth of shares (7,412 units at $20.62), increasing direct ownership by 70% to 508,849 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERChief Financial Officer Goldan Keith A. acquired $10,337 worth of shares (1,219 units at $8.48), was granted 52,250 shares and sold $42,931 worth of shares (2,082 units at $20.62), increasing direct ownership by 56% to 143,839 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Jarrett Jennifer was granted 24,000 shares, increasing direct ownership by 27% to 114,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Huber Martin H. Jr. was granted 24,000 shares, increasing direct ownership by 30% to 103,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERHead of R&D, CMO Botwood Nicholas A.J. was granted 60,000 shares, increasing direct ownership by 171% to 95,165 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Podlesak Dennis was granted 48,000 shares, increasing direct ownership by 25% to 239,763 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Rizo Aleksandra was granted 24,000 shares, increasing direct ownership by 96% to 49,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Katkin Keith was granted 24,000 shares, increasing direct ownership by 24% to 124,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- INSIDERDirector Legault Pierre was granted 24,000 shares, increasing direct ownership by 27% to 114,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- PRSyndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech SummitNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time. About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Co
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Syndax Pharmaceuticals Inc.SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)